Top

BMC Psychiatry

Published in:

Open Access 01-12-2020 | Antidepressant Drugs | Research article

Prevalence of QTc interval prolongation and its associated risk factors among psychiatric patients: a prospective observational study

Authors: Zahid Ali, Mohammad Ismail, Zahid Nazar, Fahadullah Khan, Qasim Khan, Sidra Noor

Published in: BMC Psychiatry | Issue 1/2020

Abstract

Background

QT interval prolongation is a growing concern worldwide, posing psychiatric patients to life-threatening fatal arrhythmias i.e., torsade de pointes. This study aimed to identify the prevalence of QT interval prolongation, its associated risk factors and prescribing patterns of QT prolonging drugs among psychiatric patients.

Method

A prospective observational study was conducted that included psychiatric patients from a tertiary care hospital and a psychiatry clinic in Peshawar, Khyber Pakhtunkhwa, Pakistan. Electrocardiogram was recorded of those patients who were using psychotropic medications for ≥7 days, aged 18 years or more, and of either gender, male or female. The Fredericia correction formula was used for measuring QTc values (corrected QT). Chi-square test was applied to estimate differences between patients with or without prolonged QTc interval whereas, logistic regression analysis was performed to identify various predictors of QT interval prolongation.

Results

Out of 405 patients, the QTc interval was prolonged in 23 (5.7%) patients including 1 (0.2%) patient with highly abnormal prolonged QTc interval (> 500 ms). QT drugs (91.6%), female sex (38.7%) and hypertension (10.6%) were the most common QT prolonging risk factors. Prolonged QTc interval was significantly higher among male patients (p = 0.007).

Conclusion

In the present study, QT interval prolongation was observed in a considerable number of psychiatric patients. While, the high prevalence of QT prolonging risk factors among these patients warrants the increased risk of fatal arrhythmias. Therefore, risk assessment and electrocardiographic monitoring, and prescription of safer alternatives are highly recommended.

Available only for authorised users

Hondeghem LM, Drug-Induced QT. Prolongation and Torsades de pointes: an all-exclusive relationship or time for an amicable separation? Drug Saf. 2018;41(1):11–7. https://doi.org/10.1007/s40264-017-0584-4.CrossRefPubMed

Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. Sci World J. 2012;2012:212178. https://doi.org/10.1100/2012/212178.CrossRef

Bhuiyan TA, Graff C, Kanters JK, Nielsen J, Melgaard J, Matz J, et al. The T-peak-T-end interval as a marker of repolarization abnormality: a comparison with the QT interval for five different drugs. Clin Drug Investig. 2015;35(11):717–24. https://doi.org/10.1007/s40261-015-0328-0.CrossRefPubMed

Vandael E, Marynissen T, Reyntens J, Spriet I, Vandenberghe J, Willems R, et al. Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium. Int J Clin Pharm. 2014;36(4):757–65. https://doi.org/10.1007/s11096-014-9953-6.CrossRefPubMed

Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest. 2005;115(8):2025–32. https://doi.org/10.1172/JCI25539.CrossRefPubMedPubMedCentral

van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol. 2010;70(1):16–23. https://doi.org/10.1111/j.1365-2125.2010.03660.x.CrossRefPubMedPubMedCentral

Woosley R.L., Heise C.W., Gallo T., Tate J., Woosley D., K.A. Romero. CredibleMeds Database. 2018. https://www.crediblemeds.org/. Accessed 25 Sept 2018.

Heemskerk CPM, Pereboom M, van Stralen K, Berger FA, van den Bemt P, Kuijper AFM, et al. Risk factors for QTc interval prolongation. Eur J Clin Pharmacol. 2018;74(2):183–91. https://doi.org/10.1007/s00228-017-2381-5.CrossRefPubMed

Nose M, Bighelli I, Castellazzi M, Martinotti G, Carra G, Lucii C, et al. Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study. Epidemiol Psychiatr Sci. 2016;25(6):532–40. https://doi.org/10.1017/S2045796015000906.CrossRefPubMed

10.

Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm. 2008;65(11):1029–38. https://doi.org/10.2146/ajhp070279.CrossRefPubMed

11.

Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67(1):26–36. https://doi.org/10.1001/archgenpsychiatry.2009.175.CrossRefPubMed

12.

Moller HJ, Seemuller F, Schennach-Wolff R, Stubner S, Ruther E, Grohmann R. History, background, concepts and current use of comedication and polypharmacy in psychiatry. Int J Neuropsychopharmacol. 2014;17(7):983–96. https://doi.org/10.1017/S1461145713000837.CrossRefPubMed

13.

Khan Q, Ismail M, Haider I, Khan F. Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study. Int J Clin Pharm. 2017;39(6):1256–64. https://doi.org/10.1007/s11096-017-0532-5.CrossRefPubMed

14.

Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy in psychiatry: a review. Mens Sana Monogr. 2013;11(1):82–99. https://doi.org/10.4103/0973-1229.104497.CrossRefPubMedPubMedCentral

15.

Comer JS, Olfson M, Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry. 2010;49(10):1001–10. https://doi.org/10.1016/j.jaac.2010.07.007.CrossRefPubMedPubMedCentral

16.

Preskorn SH, Flockhart D. Blog archives 2006 guide to psychiatric Drug interactions. Primary Psychiatry. 2006;13(4):35–64.

17.

Möller H-J, Seemüller F, Schennach-Wolff R, Stübner S, Rüther E, Grohmann R. History, background, concepts and current use of comedication and polypharmacy in psychiatry. Int J Neuropsychopharmacol. 2014;17(7):983–96.CrossRef

18.

Ghaemi SN, editor. Polypharmacy in psychiatry. Marcel Dekker, Inc., New York; 2002:101–32.

19.

PRESKORN SH, LACEY RL. Polypharmacy: when is it rational? J Psychiatr Pract. 2007;13(2):97–105.CrossRef

20.

Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243–52. https://doi.org/10.1056/NEJMoa052964.CrossRefPubMed

21.

Association AP. Practice guideline for the treatment of patients with bipolar disorder (revision). American Psychiatric Pub; 2002.

22.

Association AP. Practice guideline for the treatment of patients with eating disorders (revision). Am J Psychiatry. 2000;157(1):1.CrossRef

23.

Wijkstra J, Lijmer J, Balk FJ, Geddes JR, Nolen WA. Pharmacological treatment for psychotic depression: Cochrane systematic review and meta-analysis. Eur Neuropsychopharmacol. 2005;15:S393.

24.

Chastang A, Renet S, Corny J, Beaussier H, Petre A, Lillo-Lelouet A, et al. Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs. Int J Clin Pharm. 2019;41(1):42–8. https://doi.org/10.1007/s11096-018-0724-7.CrossRefPubMed

25.

Coughtrie AL, Behr ER, Layton D, Marshall V, Camm AJ, Shakir SAW. Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort. BMJ Open. 2017;7(10):e016627. https://doi.org/10.1136/bmjopen-2017-016627.CrossRefPubMedPubMedCentral

26.

Viola R, Csukonyi K, Doro P, Janka Z, Soos G. Reasons for polypharmacy among psychiatric patients. Pharm World Sci. 2004;26(3):143–7. https://doi.org/10.1023/B:PHAR.0000026800.13888.b0.CrossRefPubMed

27.

Rodriguez-Leal CM, Lopez-Lunar E, Carrascosa-Bernaldez JM, Provencio-Arranz RM. Electrocardiographic surveillance in a psychiatric institution: avoiding iatrogenic cardiovascular death. Int J Psychiatry Clin Pract. 2017;21(1):64–6. https://doi.org/10.1080/13651501.2016.1234623.CrossRefPubMed

28.

Berling I, Gupta R, Bjorksten C, Prior F, Whyte IM, Berry S. A review of ECG and QT interval measurement use in a public psychiatric inpatient setting. Australas Psychiatry. 2018;26(1):50–5. https://doi.org/10.1177/1039856217726212.CrossRefPubMed

29.

Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54(1):1–13. https://doi.org/10.1016/j.psym.2012.11.001.CrossRefPubMed

30.

Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Medica Scandinavica. 1920;53(1):469–86.CrossRef

31.

Bazett HC. An analysis of the time relations of electrocardiograms. Heart. 1920;7:353–70.

32.

Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is "normal". J Cardiovasc Electrophysiol. 2006;17(3):333–6. https://doi.org/10.1111/j.1540-8167.2006.00408.x.CrossRefPubMed

33.

Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013–22. https://doi.org/10.1056/NEJMra032426.CrossRefPubMed

34.

Micromedex-DrugReax®. Micromedex Drug-Reax®. Greenwood Village: Truven Health Analytics; 2018. https://www.micromedexsolutions.com/home/dispatch/ssl/true. Accessed 8 Sept 2018.

35.

Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand. 1996;93(4):311–3. https://doi.org/10.1111/j.1600-0447.1996.tb10653.x.CrossRefPubMed

36.

Mackin P, Young AH. QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study. J Clin Psychiatry. 2005;66(11):1386–91.CrossRef

37.

Girgis S, Huckstep B, Oakley J, Ferriter M, Nikolaou V. QTc-interval abnormalities in a forensic population. Crim Behav Ment Health. 2007;17(2):75–88. https://doi.org/10.1002/cbm.630.CrossRefPubMed

38.

Ozeki Y, Aoki T, Fujii K, Kurimoto N, Takahashi J, Ishida N, et al. Risk factors of QT interval prolongation in Japanese patients with schizophrenia. Int J Neuropsychopharmacol. 2008;11:149.

39.

Girardin FR, Gex-Fabry M, Berney P, Shah D, Gaspoz JM, Dayer P. Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG screening outcome in psychiatry study. Am J Psychiatry. 2013;170(12):1468–76. https://doi.org/10.1176/appi.ajp.2013.12060860.CrossRefPubMed

40.

Poncet A, Gencer B, Blondon M, Gex-Fabry M, Combescure C, Shah D, et al. Electrocardiographic screening for prolonged QT interval to reduce sudden cardiac death in psychiatric patients: a cost-effectiveness analysis. PLoS One. 2015;10(6):e0127213. https://doi.org/10.1371/journal.pone.0127213.CrossRefPubMedPubMedCentral

41.

Miura N, Saito T, Taira T, Umebachi R, Inokuchi S. Risk factors for QT prolongation associated with acute psychotropic drug overdose. Am J Emerg Med. 2015;33(2):142–9. https://doi.org/10.1016/j.ajem.2014.09.048.CrossRefPubMed

42.

Sadanaga T, Sadanaga F, Yao H, Fujishima M. Abnormal QT prolongation and psychotropic drug therapy in psychiatric patients: significance of bradycardia-dependent QT prolongation. J Electrocardiol. 2004;37(4):267–73. https://doi.org/10.1016/j.jelectrocard.2004.07.001.CrossRefPubMed

43.

Ramos-Rios R, Arrojo-Romero M, Paz-Silva E, Carballal-Calvo F, Bouzon-Barreiro JL, Seoane-Prado J, et al. QTc interval in a sample of long-term schizophrenia inpatients. Schizophr Res. 2010;116(1):35–43. https://doi.org/10.1016/j.schres.2009.09.041.CrossRefPubMed

44.

Yang FD, Wang XQ, Liu XP, Zhao KX, Fu WH, Hao XR, et al. Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics. Psychopharmacology. 2011;216(1):9–16. https://doi.org/10.1007/s00213-011-2188-5.CrossRefPubMed

45.

Rabkin SW. Impact of age and sex on QT prolongation in patients receiving Psychotropics. Can J Psychiatr. 2015;60(5):206–14. https://doi.org/10.1177/070674371506000502.CrossRef

46.

Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355(9209):1048–52. https://doi.org/10.1016/S0140-6736(00)02035-3.CrossRefPubMed

47.

Ozeki Y, Fujii K, Kurimoto N, Yamada N, Okawa M, Aoki T, et al. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2010;34(2):401–5. https://doi.org/10.1016/j.pnpbp.2010.01.008.CrossRef

48.

Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424–32. https://doi.org/10.1007/s11096-017-0446-2.CrossRefPubMed

Title: Prevalence of QTc interval prolongation and its associated risk factors among psychiatric patients: a prospective observational study
Authors: Zahid Ali
Mohammad Ismail
Zahid Nazar
Fahadullah Khan
Qasim Khan
Sidra Noor
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Antidepressant Drugs
Antidepressant Drugs
Published in: BMC Psychiatry / Issue 1/2020
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-020-02687-w

2024 ASCO Annual Meeting

Springer Medicine

Prevalence of QTc interval prolongation and its associated risk factors among psychiatric patients: a prospective observational study

Abstract

Background

Method

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

The potential impact of an anti-stigma intervention on mental health help-seeking attitudes among university students

Cognitive performance in children and adolescents at high-risk for obsessive-compulsive disorder

Prevalence and predictors of anxiety and depressive symptoms among patients diagnosed with oral cancer in China: a cross-sectional study

Bouldering psychotherapy is more effective in the treatment of depression than physical exercise alone: results of a multicentre randomised controlled intervention study

Depression treatment in Germany – using claims data to compare a collaborative mental health care program to the general practitioner program and usual care in terms of guideline adherence and need-oriented access to psychotherapy

Acceptability, equity, and feasibility of using antipsychotics in children and adolescents with autism spectrum disorder: a systematic review